Novo Nordisk A/S B

Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
  • TickerNOVO B
  • ISINDK0060534915
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

Nurhayati Wan

Novo Nordisk

Nurhayati Wan

Novo Nordisk

1 director sold

A director at Novo Nordisk AS sold 18,000 shares at 335.894DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK410.00) - 2019 guidance raised

Novo Nordisk (NOVOB DC, Buy) - 2019 guidance raised (18 pages)

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK410.00) - Strong IO growth continues

Novo Nordisk reported strong Q2 sales growth in local currencies of c4% YOY (c12% in IO and c0% in NAO), and also beat consensus on operating profit (delivering c4% growth in local currencies). The 2019 sales growth guidance in local terms was upgraded to 4–6% (previously 2–5%), and operating profit growth is now expected to be 4–6% (previously 2–6%). We expect positive EPS consensus revisions of 1–2% for 2019e and the share price to be up 2–3% today.

Martial Descoutures ...
  • Pierre Corby

Novo Nordisk : Trend should continue

>Q2 earnings report driven by GLP1 - Novo Nordisk has just reported its Q2 results. Sales were +2% higher than forecast and EBIT was +3.4% higher than estimated. In short, sales continued to be driven by the GLP1 franchise which was up +25% while the insulin franchise remained under pressure (-4% at constant currency - cc). However, given the high financial expenses (forex hedging), EPS came to just DKK 4.03 (vs DKK 4.12 forecast). The company took the opportunity of ...

Martial Descoutures ...
  • Pierre Corby

Novo Nordisk : Une tendance qui devrait se poursuivre

>Une publication du T2 tirée par le GLP1 - Novo Nordisk vient de publier ses résultats du T2 qui se révèlent +2% au-dessus des attentes en topline et +3.4% au niveau de l’EBIT. Brièvement, les ventes restent tirées par la franchise GLP1 en hausse de +25% alors que la franchise insuline reste sous pression (-4% à tcc). Cependant du fait de frais financiers élevés (hedging des changes), le BPA atteint seulement 4.03 DKK (vs 4.12 DKK att). La société profite de cett...

Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK410.00) - IO to drive growth in Q2

We expect IO to deliver continued good organic growth but see a slowdown in Q2 compared to Q1’s c13%. In the US we forecast increased headwinds from the coverage gap effect. We estimate c3.8% sales growth in constant currency YOY and an EBIT margin of 44.3%. We believe the 2019 organic growth guidance will be narrowed towards the high end of the range and reiterate our BUY and DKK410 target price.

1 director sold

A director at Novo Nordisk AS sold 18,000 shares at 335.894DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Håkon Astrup ...
  • Jørgen Lian
  • Karl-Johan Bonnevier
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Benoit Valleaux ...
  • Emira Sagaama
  • Harald Eggeling
  • Jean Sassus
  • Khaled Ben Amor
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 08/09/2019

...

Benoit Valleaux ...
  • Emira Sagaama
  • Harald Eggeling
  • Jean Sassus
  • Khaled Ben Amor
  • Louis Boujard
  • Martial Descoutures
  • Matthias Desmarais
  • Philippe Ourpatian
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 09/08/2019

...

Mats Bye ...
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

François Maury ...
  • Georges Dieng
  • Team Pharma

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/28/2019

...

Nurhayati Wan

Novo Nordisk

Nurhayati Wan

Novo Nordisk

With a more favourable environment, NOVO NORDISK A/S improves to Slightly Positive

NOVO NORDISK A/S (DK), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date July 2, 2019, the closing price was DKK 344.10 and its potential was estimated at DKK 366.97.

Nurhayati Wan

Novo Nordisk

Nurhayati Wan

Novo Nordisk

MarketLine Department

F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report

F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report Summary F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights F. Hoffmann-La Roche Ltd (Roche or 'the company') is one of the leading research-focused healthcare groups in the world. It is involved in the discovery, development and commercialization of innovative therapeut...

MarketLine Department

F. Hoffmann-La Roche Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's F. Hoffmann-La Roche Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by F. Hoffmann-La Roche Ltd since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive a...

MarketLine Department

Antares Pharma, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Antares Pharma, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Antares Pharma, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage...

Expert Corporate Governance Service (ECGS)

Novo Nordisk, March 21 2019

In general, Novo Nordisk is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 5.3 (b), it is proposed to newly appoint Ms. Laurence Debroux as Member of the board of directors. Although Ms. Debroux would be considered independent in accordance with provision 3.2.1 of the Danish Recommendations on Corporate Governance, ECGS has concerns over her aggregate time commitments. Ms. Debroux is currently already serving as CFO of Heineken N.V. (listed) and non-executive director of Exor N.V. (listed). Taking into account he...

Novo Nordisk – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

The U.S. has continued to separate itself from broad emerging market and developed international indexes. Thankfully, one positive is that MSCI EM and MSCI EAFE have been able to stabilize from a price perspective despite relative strength weakness vs. MSCI ACWI... see charts below. In today's report we scour the globe for attractive investments in an environment where selectivity is key. • Emerging markets. There is still not much to like about broad EM as the MSCI Emerging Markets index has remained weak following price and relative strength breakdowns. Remain underweight broad EM and be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch